Loading
A phase 2 trial of Adagrasib, Pembrolizumab, Pemetrexed, Carboplatin and Cisplatin in non-small-cell lung cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation is a phase 2 interventional study registered as NCT05609578 by Mirati Therapeutics Inc., with 90 participants enrolled, started 2022-11-22 and due to reach its primary completion in 2026-09-30. Interventions recorded: Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed and Cisplatin/Carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin and the tag pipeline.
Shares Adagrasib, KRAS & RAS inhibitors, Pemetrexed, Bristol Myers Squibb and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/